The Fort Worth Press - The scientist rewriting DNA, and the future of medicine

USD -
AED 3.673042
AFN 65.000368
ALL 79.73251
AMD 363.440403
ANG 1.790365
AOA 918.000367
ARS 1517.997704
AUD 1.402304
AWG 1.8
AZN 1.70397
BAM 1.705151
BBD 2.014743
BDT 122.842733
BGN 1.683441
BHD 0.377041
BIF 3000
BMD 1
BND 1.278286
BOB 9.828548
BRL 5.142041
BSD 1.000371
BTN 95.852241
BWP 13.566297
BYN 3.025994
BYR 19600
BZD 2.011918
CAD 1.39975
CDF 2311.000362
CHF 0.822098
CLF 0.024299
CLP 959.460396
CNY 6.69765
CNH 6.703907
COP 3184.33
CRC 447.525011
CUC 1
CUP 26.5
CVE 96.250394
CZK 21.197204
DJF 177.720393
DKK 6.508104
DOP 59.042263
DZD 133.76304
EGP 52.246159
ERN 15
ETB 163.400976
EUR 0.870604
FJD 2.215904
FKP 0.749304
GBP 0.746547
GEL 2.603861
GGP 0.749304
GHS 11.524327
GIP 0.749304
GMD 73.503851
GNF 8794.552556
GTQ 7.633994
GYD 209.29239
HKD 7.84505
HNL 26.85435
HRK 6.559704
HTG 130.743913
HUF 317.150388
IDR 17812.1
ILS 3.03663
IMP 0.749304
INR 95.98635
IQD 1310.490638
IRR 1374600.000352
ISK 121.190386
JEP 0.749304
JMD 157.960584
JOD 0.70904
JPY 156.880385
KES 129.510385
KGS 87.450384
KHR 4054.195438
KMF 428.00035
KPW 900.000318
KRW 1386.040383
KWD 0.30816
KYD 0.833682
KZT 447.238218
LAK 22425.000349
LBP 89550.000349
LKR 331.11734
LRD 173.066192
LSL 16.263563
LTL 2.95274
LVL 0.60489
LYD 6.350381
MAD 9.478186
MDL 17.581258
MGA 4336.662409
MKD 53.645926
MMK 2099.69268
MNT 3599.361607
MOP 8.083211
MRU 40.24412
MUR 47.570378
MVR 15.450378
MWK 1734.672526
MXN 17.22895
MYR 4.083704
MZN 63.910377
NAD 16.263705
NGN 1331.730377
NIO 36.809228
NOK 9.410376
NPR 153.367772
NZD 1.748864
OMR 0.385493
PAB 1.000379
PEN 3.37569
PGK 4.45264
PHP 62.910375
PKR 277.27411
PLN 3.79885
PYG 5930.433797
QAR 3.65652
RON 4.582404
RSD 101.965038
RUB 84.392305
RWF 1469.536863
SAR 3.726614
SBD 8.000512
SCR 14.067111
SDG 601.503676
SEK 9.829604
SGD 1.276104
SHP 0.747524
SLE 24.650371
SLL 20969.491881
SOS 571.677674
SRD 37.945504
STD 20697.981008
STN 21.360535
SVC 8.753575
SYP 13002.000254
SZL 16.258419
THB 33.340369
TJS 9.228308
TMT 3.51
TND 2.942646
TOP 2.40776
TRY 48.767038
TTD 6.790907
TWD 31.780367
TZS 2649.996038
UAH 44.694758
UGX 3945.963147
UYU 40.228081
UZS 11844.198871
VES 847.485104
VND 26022
VUV 118.29149
WST 2.754822
XAF 571.078855
XAG 0.015096
XAU 0.000228
XCD 2.70255
XCG 1.802885
XDR 0.707052
XOF 571.078855
XPF 103.976042
YER 236.550363
ZAR 16.269804
ZMK 9001.203584
ZMW 19.662326
ZWL 321.999592
SSP 5664.022588
MXV 1.953281
  • CMSC

    0.0400

    20.71

    +0.19%

  • GSK

    -0.8400

    50.22

    -1.67%

  • JRI

    -0.0600

    11.55

    -0.52%

  • NGG

    -0.8000

    76.8

    -1.04%

  • BTI

    -0.1900

    55.83

    -0.34%

  • CMSD

    0.0000

    20.45

    0%

  • AZN

    -0.0600

    166.08

    -0.04%

  • BCC

    0.1600

    75.69

    +0.21%

  • RBGPF

    -1.6900

    68.3

    -2.47%

  • RYCEF

    0.7100

    20

    +3.55%

  • RIO

    -0.6700

    97.37

    -0.69%

  • BCE

    -0.2200

    22.06

    -1%

  • VOD

    -0.5700

    16.95

    -3.36%

  • RELX

    -0.9700

    33.41

    -2.9%

  • BP

    -0.8400

    44.58

    -1.88%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: © Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

C.M.Harper--TFWP